# Therorna

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therorna

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.therorna.com
- Total disclosed funding: $42M
- Latest round: Series A (Jun 21, 2022)
- Investors on record: 6

## About

Founded in 2021 and based in Beijing, China, Yuan Yin (Beijing) Biotechnology Co., Ltd. operates as a biotechnology company that focuses on the research and application of circular RNA technology in the field of innovative drugs and therapeutics. The company's founder, Wei Wensheng, is the director of Peking University's Genome Editing Research Center. The company's CEO, Daniel Tang, was the COO of Vanshi Biomedical. The company's CMO, Rick Xu, was the senior director of Jilin Wantong Group Co., Ltd.

The company focuses on developing new vaccines and innovative therapies by using circular RNA technology.

The company will focus on the pre-clinical and clinical studies for new drug pipelines.

## Funding rounds

- Series A, Jun 21, 2022, $42M — Tencent Investment, MSA Capital, Cenova Ventures, Quan Capital, Sherpa Healthcare Partners, 3H Health Investment
- Series A, May 11, 2022 — Tencent Investment

## Investors

- Tencent Investment — Series A
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series A
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series A
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series A